Why Veradermics Stock Fell Today | Quiver Quantitative

Veradermics (MANE) is down 14.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears to be a case of investors selling into fresh clinical data rather than reacting to a clearly negative headline. Veradermics released positive Phase 2 female pattern hair loss results for VDPHL01, but the study was small and open-label, which may have left traders wanting stronger, later-stage evidence after the stock’s big run earlier this year. This could also be because expectations had already moved higher following prior male-study data and the company’s sharp share-price gains.

Details:

Veradermics announced positive topline results from Study 207 in women, with reported hair-count gains at six months and no treatment-related serious adverse events or cardiac adverse events of special interest.

The female readout came from an open-label Phase 2 study with 28 participants, which can make investors cautious because the dataset is earlier-stage and less rigorous than a placebo-controlled pivotal result.

The company said topline data from its registration-directed female Study 306 is expected in the first half of 2027, so investors still face a longer wait for a more decisive catalyst.

Veradermics had already posted strong earlier momentum after positive male Phase 2/3 data and had also raised capital in an upsized April equity offering, which can set up profit-taking when new updates arrive.

Sources:

Veradermics, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MANE Insider Trading Activity

$MANE insiders have traded $MANE stock on the open market 26 times in the past 6 months. Of those trades, 26 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $MANE stock by insiders over the last 6 months:

PATRICK G ENRIGHT has made 2 purchases buying 1,075,000 shares for an estimated $18,275,000 and 0 sales.
CAPITAL PARTNERS V, LLC LONGITUDE has made 2 purchases buying 1,075,000 shares for an estimated $18,275,000 and 0 sales.
CAPITAL MANAGEMENT, LLC SUVRETTA has made 19 purchases buying 282,674 shares for an estimated $10,542,477 and 0 sales.
JOHN W CHILDS purchased 294,117 shares for an estimated $4,999,989
VLAD CORIC has made 2 purchases buying 117,646 shares for an estimated $1,999,982 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MANE Hedge Fund Activity

We have seen 68 institutional investors add shares of $MANE stock to their portfolio, and 0 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

SUVRETTA CAPITAL MANAGEMENT, LLC added 4,168,970 shares (+inf%) to their portfolio in Q1 2026, for an estimated $263,270,455
SR ONE CAPITAL MANAGEMENT, LP added 2,401,868 shares (+inf%) to their portfolio in Q1 2026, for an estimated $151,677,964
CITADEL ADVISORS LLC added 1,825,672 shares (+inf%) to their portfolio in Q1 2026, for an estimated $115,291,186
FMR LLC added 1,792,909 shares (+inf%) to their portfolio in Q1 2026, for an estimated $113,222,203
VIKING GLOBAL INVESTORS LP added 1,690,555 shares (+inf%) to their portfolio in Q1 2026, for an estimated $106,758,548
SIREN, L.L.C. added 1,505,374 shares (+inf%) to their portfolio in Q1 2026, for an estimated $95,064,368
ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,100,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $69,465,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MANE Analyst Ratings

Wall Street analysts have issued reports on $MANE in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 06/02/2026
Cantor Fitzgerald issued a "Overweight" rating on 03/02/2026

To track analyst ratings and price targets for $MANE, check out Quiver Quantitative's $MANE forecast page.

$MANE Price Targets

Multiple analysts have issued price targets for $MANE recently. We have seen 5 analysts offer price targets for $MANE in the last 6 months, with a median target of $135.0.

Here are some recent targets:

Roger Song from Jefferies set a target price of $182.0 on 07/07/2026
Rami Katkhuda from LifeSci Capital set a target price of $135.0 on 06/16/2026
Serge Belanger from Needham set a target price of $136.0 on 06/02/2026
Geoff Meacham from Citigroup set a target price of $135.0 on 05/18/2026
Marc Goodman from Leerink Partners set a target price of $90.0 on 04/22/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.